Last reviewed · How we verify

NCT04549805: PRECISE-CTCA

Troponin to Risk Stratify Patients for Computed Tomography Coronary Angiography

Completed Last updated 11 March 2021
What this trial tests

trial testing Computed Tomography Coronary Angiography in Coronary Artery Disease in 250 participants. Completed in 6 October 2020.

Timeline
4 December 2018
Primary endpoint
6 October 2020
6 October 2020

Quick facts

Lead sponsorUniversity of Edinburgh
StatusCompleted
Study typeOBSERVATIONAL
Enrollment250
Start date4 December 2018
Primary completion6 October 2020
Estimated completion6 October 2020
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Edinburgh

Who can join

30 and older, any sex, with Coronary Artery Disease or Acute Coronary Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Most patients presenting to hospital with chest pain are discharged home without further tests once a heart attack has been ruled out. Current strategies to assess patients with a suspected heart attack involve blood tests to measure troponin, a protein released into the bloodstream when the heart muscle is damaged. Despite having had a heart attack ruled-out, some patients have unrecognised coronary heart disease and are at risk of having a heart attack in the future. However, we do not know what is the best approach to identify and treat these patients. This study will use a heart scan known as computed tomography coronary angiogram (CTCA) to look for underlying coronary heart disease in patients who have had a heart attack ruled out. In an earlier study, we performed this scan in patients referred to the outpatient cardiology clinic with stable chest pain and found that this improved the diagnosis of coronary heart disease, leading to improvement in patient care that prevented many future heart attacks. Our research has also demonstrated that troponin levels below the threshold used to diagnose a heart attack identify those who are at greater risk of having a heart attack in the future. The aim of this study is to confirm whether these low levels of troponin can identify patients who have underlying coronary heart disease and may benefit from further testing and preventative treatment.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Troponin-Guided Coronary Computed Tomographic Angiography After Exclusion of Myocardial Infarction.
    Lee KK, Bularga A, O'Brien R, Ferry AV, et al · · 2021 · cited 32× · PMID 34593122 · DOI 10.1016/j.jacc.2021.07.055
  2. Coronary low-attenuation plaque and high-sensitivity cardiac troponin.
    Meah MN, Wereski R, Bularga A, van Beek EJR, et al · · 2023 · cited 12× · PMID 36631142 · DOI 10.1136/heartjnl-2022-321867
  3. Risk scores and coronary artery disease in patients with suspected acute coronary syndrome and intermediate cardiac troponin concentrations.
    Perez-Vicencio D, Thurston AJF, Doudesis D, O'Brien R, et al · · 2024 · cited 2× · PMID 39097328 · DOI 10.1136/openhrt-2024-002755
  4. Risk scores and coronary artery disease in patients with suspected acute coronary syndrome and intermediate cardiac troponin concentrations
    Perez-Vicencio D, Thurston AJ, Doudesis D, O’Brien R, et al · · 2024 · DOI 10.1101/2024.04.30.24306662

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other University of Edinburgh trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04549805.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing